Citius Oncology stock rises after expanding LYMPHIR distribution network

Published 15/07/2025, 14:42
© Reuters.

Investing.com -- Citius Oncology, Inc. (NASDAQ:CTOR) stock rose 4.1% after announcing a distribution services agreement with Cencora for its FDA-approved immunotherapy LYMPHIR.

The agreement with Cencora, formerly known as AmerisourceBergen (NYSE:COR), will expand the distribution network for LYMPHIR (denileukin diftitox-cxdl), which received FDA approval in August 2024 for treating adults with relapsed or refractory cutaneous T-cell lymphoma. Under the agreement, Cencora will serve as a wholesale distributor for LYMPHIR, providing specialty distribution services across its network.

This new arrangement builds upon a previously announced distribution agreement, further strengthening the company’s distribution strategy for the recently approved drug.

"Our agreement with Cencora adds further depth to our distribution strategy and strengthens our ability to deliver LYMPHIR to treatment centers across the country," said Leonard Mazur, Chairman and CEO of Citius Oncology and parent company Citius Pharmaceuticals.

LYMPHIR is indicated for Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. The drug is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments.

Citius Oncology estimates the initial market for LYMPHIR exceeds $400 million. The company is a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), which owns 92% of Citius Oncology.

The drug carries a boxed warning for capillary leak syndrome, which can be life-threatening or fatal. Common adverse reactions include increased transaminases, decreased albumin, nausea, edema, decreased hemoglobin, fatigue, and musculoskeletal pain.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.